BIJUVA is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus.
The Company plans to hold an Investor Day in New York on June 10.
Shares are up 7% premarket.
Now read: CVS: This Is Disgusting »
Subscribe for full text news in your inbox